Abstract
Amyotrophic lateral sclerosis (ALS) is a severe progressive neurodegenerative disease. The cause is unknown, but genetic abnormalities have been identified in subjects with familial ALS and also in subjects with sporadic ALS. Environmental factors such as occupational exposure have been shown to be risk factors for the development of ALS. Patients differ in their clinical features and differ in the clinical course of disease. Immune abnormalities have been found in the central nervous system by pathological studies and also in the blood and CSF of subjects with ALS. Inflammation and immune abnormalities are also found in animals with a model of ALS due to mutations in the SOD1 gene. Previously it has been considered that immune abnormalities might contribute to the pathogenesis of disease. However more recently it has become apparent that an immune response can occur as a response to damage to the nervous system and this can be protective.
Keywords: Amyotrophic lateral sclerosis, biomarkers, immunity, inflammation, lymphocytes, protective immunity, T cells, neurodegenerative diseases, autoimmune diseases, dementia, heterogeneity, astrocytes, gene expression, nuclear medicine technology, PET imaging
Current Molecular Medicine
Title: The Role of Immune and Inflammatory Mechanisms in ALS
Volume: 11 Issue: 3
Author(s): P. A. McCombe and R. D. Henderson
Affiliation:
Keywords: Amyotrophic lateral sclerosis, biomarkers, immunity, inflammation, lymphocytes, protective immunity, T cells, neurodegenerative diseases, autoimmune diseases, dementia, heterogeneity, astrocytes, gene expression, nuclear medicine technology, PET imaging
Abstract: Amyotrophic lateral sclerosis (ALS) is a severe progressive neurodegenerative disease. The cause is unknown, but genetic abnormalities have been identified in subjects with familial ALS and also in subjects with sporadic ALS. Environmental factors such as occupational exposure have been shown to be risk factors for the development of ALS. Patients differ in their clinical features and differ in the clinical course of disease. Immune abnormalities have been found in the central nervous system by pathological studies and also in the blood and CSF of subjects with ALS. Inflammation and immune abnormalities are also found in animals with a model of ALS due to mutations in the SOD1 gene. Previously it has been considered that immune abnormalities might contribute to the pathogenesis of disease. However more recently it has become apparent that an immune response can occur as a response to damage to the nervous system and this can be protective.
Export Options
About this article
Cite this article as:
A. McCombe P. and D. Henderson R., The Role of Immune and Inflammatory Mechanisms in ALS, Current Molecular Medicine 2011; 11(3) . https://dx.doi.org/10.2174/156652411795243450
DOI https://dx.doi.org/10.2174/156652411795243450 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Editorial (Thematic Issue: GABAergic Modulation as Treatment Strategy: Consideration of Several Diseases)
Current Pharmaceutical Design Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Conformational Changes and Aggregation of Expanded Polyglutamine Proteins as Therapeutic Targets of the Polyglutamine Diseases: Exposed β-Sheet Hypothesis
Current Pharmaceutical Design Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Current Pharmaceutical Design Mitochondria: A Promising Target for Anticancer Alkaloids
Current Topics in Medicinal Chemistry Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Parkinson's Disease: From Genetics to Clinical Practice
Current Genomics Memory Enhancing Effect of Black Pepper in the AlCl3 Induced Neurotoxicity Mouse Model is Mediated Through Its Active Component Chavicine
Current Pharmaceutical Biotechnology Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Targeting ENaC as a Molecular Suspect in Cystic Fibrosis
Current Drug Targets Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology Formulation and In Vitro Evaluation of Gelatin Nanospheres for the Oral Delivery of Selegiline
Current Nanoscience Editorial [Hot Topic: Galectin-1 as an Essential Factor in Nervous System (Guest Editor: Hidenori Horie)]
Current Drug Targets Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine